A BMJ journal has retracted a medical case report about a couple in the United Kingdom who were infected by parasitic worms while on a Caribbean cruise.
The paper in BMJ Case Reports included graphic photos of the patients’ buttocks, the site of the infection, which were republished within a week by UK tabloids.
Specifics about when and why the journal retracted the paper remains unclear. BMJ Publishing Group, the journal, and the corresponding author have not responded to multiple requests for comment.
A UK-based lawyer, who has represented doctors in cases that touch on publishing and media law, told us there could be legal trouble. Martin Soames, of London firm Simons Muirhead & Burton, told Retraction Watch that UK laws governing patient confidentiality or protection of personal information could apply, raising problems for both the publisher and the doctors who wrote the paper. [See update at the end of the post, in which the editor says the paper was removed, and “does not consider that there are any issues of liability.”] Continue reading BMJ journal pulls case report after UK tabloids publish graphic photos
Brachycephaly describes a condition where the back of the head is abnormally flat and trichomegaly refers to extra length, curling, pigmentation, or thickness of the eyelashes.
Marc Pieterse, of the Netherlands, has a son with the rare RPS23 mutation, one of two known patients in the world. The mutation affects ribosomes, cell components involved in protein production. On Aug. 9, we reported on Pieterse’s crusade against OMIM’s original name for the condition, which dubbed it a syndrome. He has feared that calling it a syndrome would “stigmatize” his son’s condition and tried to get the paper underpinning the OMIM entry retracted. The American Journal of Human Genetics has said it will not retract the paper.
The father of a boy with a rare genetic mutation has accused a scientist of exploiting his child by proclaiming the defect a “genetic syndrome” and naming it after herself.
At an impasse with scientists investigating, publicizing, and interpreting his son’s condition, the father seems willing to use any leverage he can muster to remove the “syndrome” entry in an online genetic disease database. Based solely on an email he obtained from the database director, the father became convinced that if the paper underpinning the entry were retracted, the syndrome would go down with it. So earlier this year, he withdrew his consent and asked the journal that published the paper for a retraction, based on improper patient consent. He has also threatened to lob accusations of research misconduct at the paper’s last author. Continue reading Fearing “stigmatization,” patient’s father seeks retraction of paper on rare genetic mutation
Psychiatry journals have retracted two papers evaluating a schizophrenia drug after a university in Japan flagged issues, such as a lack of written informed consent.
The papers—published in Human Psychopharmacology: Clinical & Experimental in 2012 and Psychiatry and Clinical Neurosciences in 2014—examined the safety and effectiveness of an antipsychotic drug in patients with schizophrenia.
According to the retraction notice in Psychiatry and Clinical Neurosciences, the ethics committee at St. Marianna University School of Medicine in Kawasaki found that “the trial included subjects who did not satisfy inclusion criteria.” For instance, not all patients provided written informed consent. But the university found no evidence for data falsification or fabrication.
A patient appears to have had a change of heart about being featured in a case report.
The patient cannot be identified in the paper published in Journal of Gastrointestinal and Liver Diseases. However, according to the retraction notice, she threatened to sue if the authors did not withdraw it. After receiving the threat, the paper’s corresponding author, Mariano Sica, told us that the authors immediately asked the journal to retract the paper.
We’ve written about similar cases where patients do not provide informed consent or withdraw it, but in this case we haven’t seen the threat ourselves.
When a group of authors decided to write up a curious case of a 35-year-old woman with a mysterious mass that took 11 years to be diagnosed, they tried repeatedly to contact the patient for her permission. When they couldn’t reach her, they published the paper anyway, removing any identifiable information.
But the report apparently included enough details for the patient to recognize herself — and when she read the paper, she asked the authors to retract it.
A psychoanalyst has retracted an award-winning 2016 paper over concerns that it contained “sensitive” patient information.
On July 15, Judith L. Mitrani, a psychoanalyst based in California, published an article that included “sensitive clinical material” about a patient. Although we do not know what prompted the concerns, on November 21, Mitrani, in agreement with the journal’s editor-in-chief and publisher, retracted the article. The author and editor told us the retraction was meant to prevent non-experts from accessing the paper and to stop other non-Wiley sites from posting it.
The article was published after it had won the journal’s essay contest in 2015.
Researchers in Ireland have retracted a case study about a rare type of cancer in a child because – contrary to what they claimed in the paper – they had not obtained the necessary permission from the parents.
In the June 2016 article, the authors stated they had received “written informed consent” from the parents to publish the case. But according to the retraction notice — issued just a few months later in October — that was not the case.
Three psychiatric studies of children contained a myriad of problems that may have put participants at greater risk than was disclosed by consent forms, according to a 2014 letter sent to hundreds of the participants and their families.
Through a public records request, we’ve obtained a copy of the letter — which lists a host of problems in the studies, ranging from enrolling ineligible patients, not informing families of the risks associated with the studies, and skipping tests intended to minimize the risks associated with lithium.
In 2013, Mani Pavuluri told the University of Illinois at Chicago that one of her study participants had been hospitalized — an event which prompted the university to halt three of her studies, launch a misconduct probe, and send letters to approximately 350 families of children participating in the research, notifying them of what happened.